Marc Uknis to Antiviral Agents
This is a "connection" page, showing publications Marc Uknis has written about Antiviral Agents.
Connection Strength
0.571
-
Uknis ME. Prophylaxis of cytomegalovirus disease in transplant patients. Am J Health Syst Pharm. 2005 Apr 15; 62(8 Suppl 1):S3-6.
Score: 0.196
-
Maertens J, Cordonnier C, Jaksch P, Poir? X, Uknis M, Wu J, Wijatyk A, Saliba F, Witzke O, Villano S. Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation. N Engl J Med. 2019 09 19; 381(12):1136-1147.
Score: 0.134
-
Papanicolaou GA, Silveira FP, Langston AA, Pereira MR, Avery RK, Uknis M, Wijatyk A, Wu J, Boeckh M, Marty FM, Villano S. Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study. Clin Infect Dis. 2019 04 08; 68(8):1255-1264.
Score: 0.129
-
Fishman JA, Emery V, Freeman R, Pascual M, Rostaing L, Schlitt HJ, Sgarabotto D, Torre-Cisneros J, Uknis ME. Cytomegalovirus in transplantation - challenging the status quo. Clin Transplant. 2007 Mar-Apr; 21(2):149-58.
Score: 0.056
-
Weng FL, Patel AM, Wanchoo R, Brahmbhatt Y, Ribeiro K, Uknis ME, Mulgaonkar S, Mathis AS. Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants. Transplantation. 2007 Feb 15; 83(3):290-6.
Score: 0.056